Iqvia (NYSE:IQV) and STARPHARMA HOLD/S (OTCMKTS:SPHRY) are both business services companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.
Valuation & Earnings
This table compares Iqvia and STARPHARMA HOLD/S’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Iqvia||$9.74 billion||2.71||$1.31 billion||$4.36||30.23|
|STARPHARMA HOLD/S||$3.79 million||75.67||-$7.97 million||N/A||N/A|
Insider and Institutional Ownership
93.6% of Iqvia shares are held by institutional investors. 6.0% of Iqvia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares Iqvia and STARPHARMA HOLD/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations for Iqvia and STARPHARMA HOLD/S, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Iqvia presently has a consensus price target of $139.29, indicating a potential upside of 5.66%. Given Iqvia’s higher probable upside, equities analysts plainly believe Iqvia is more favorable than STARPHARMA HOLD/S.
Volatility and Risk
Iqvia has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, STARPHARMA HOLD/S has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.
Iqvia beats STARPHARMA HOLD/S on 10 of the 12 factors compared between the two stocks.
Iqvia Company Profile
IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Integrated Engagement Services segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company serves pharmaceutical, biotechnology, device and diagnostic, and healthcare companies. IQVIA Holdings Inc. has a strategic alliance with MuleSoft, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
STARPHARMA HOLD/S Company Profile
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials for the treatment of a range of tumors, such as breast, prostate, and lung; and DEP cabazitaxel that is in Phase 1/2 clinical trial for solid tumors, as well as DEP irinotecan, an anti-cancer drug used to treat colorectal cancer. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.